{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:31:36Z","timestamp":1769920296689,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education","award":["2021R1I1A1A010445000"],"award-info":[{"award-number":["2021R1I1A1A010445000"]}]},{"name":"Ministry of Education","award":["2020R1A6A1A03043528"],"award-info":[{"award-number":["2020R1A6A1A03043528"]}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS601"],"award-info":[{"award-number":["21153MFDS601"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A2C1009224"],"award-info":[{"award-number":["2020R1A2C1009224"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study comprehensively investigated clinical outcomes associated with renin angiotensin system inhibitor-based dual antihypertensive regimens in non-dialysis chronic kidney disease (CKD) patients<jats:bold>.<\/jats:bold> Keyword searches of databases were performed per PRISMA-NMA guidelines. Frequentist network meta-analysis were conducted with 16 head-to-head randomized controlled trials. The effect sizes of dichotomous and continuous variables were estimated with odds ratio (OR) and standard mean differences (SMD), respectively. The protocol is registered in PROSPERO (CRD42022365927). Dual antihypertensive regimens with combination of angiotensin receptor blockers (ARB) and calcium channel blockers (CCB) demonstrated substantially reduced odd of major cardiovascular disease (CVD) events over other regimens including angiotensin converting enzyme inhibitor (ACEI) monotherapy (OR 3.19) and ARB monotherapy (OR 2.64). Most significant reductions in systolic (SBP) and diastolic blood pressure (DBP) were observed with ARB-based CCB dual regimen over ACEI monotherapy (SMD 17.60 SBP and 9.40 for DBP), ACEI-based CCB regimen (SMD 12.90 for SBP and 9.90 for DBP), and ARB monotherapy (SMD 13.20 for SBP and 5.00 for DBP). However, insignificant differences were noticed for the odds of hyperkalemia, end stage renal disease progression, and all-cause mortality. ARB-based CCB regimen has the greatest benefits on BP reduction as well as major CVD risks in non-dialysis CKD patients.<\/jats:p>","DOI":"10.1038\/s41598-023-32266-4","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:03:06Z","timestamp":1680879786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis"],"prefix":"10.1038","volume":"13","author":[{"given":"Miseung","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy Jeong","family":"Rhie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"32266_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99, S1\u2013S87 (2021).","journal-title":"Kidney Int"},{"key":"32266_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"32266_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5455\/jcmr.2022.13.02.05","volume":"13","author":"F Meziri","year":"2022","unstructured":"Meziri, F., Brahimi, F. Z. & Dorbane, C. Modulation of oxidative stress in chronic kidney disease patients with different physiopathological conditions. J. Complement. Med. Res. 13, 29\u201329 (2022).","journal-title":"J. Complement. Med. Res."},{"key":"32266_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku, E., Lee, B. J., Wei, J. & Weir, M. R. Hypertension in CKD: Core curriculum 2019. Am. J. Kidney Dis. 74, 120\u2013131 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"32266_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.ackd.2014.12.001","volume":"22","author":"E Judd","year":"2015","unstructured":"Judd, E. & Calhoun, D. A. Management of hypertension in CKD: beyond the guidelines. Adv. Chronic Kidney Dis. 22, 116\u2013122 (2015).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"32266_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., B\u00f6hm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"32266_CR7","first-page":"e134","volume":"29","author":"TJ Hameed","year":"2022","unstructured":"Hameed, T. J., Ibraheem, M. M. & Mezher, M. A. Estimation of Renin enzyme activity and some biochemical parameters among chronic renal failure patients in Tikrit city. J. Popul. Ther. Clin. Pharmacol. 29, e134\u2013e139 (2022).","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"32266_CR8","doi-asserted-by":"publisher","first-page":"e009992","DOI":"10.1161\/JAHA.118.009992","volume":"7","author":"E Ku","year":"2018","unstructured":"Ku, E., McCulloch, C. E., Vittinghoff, E., Lin, F. & Johansen, K. L. Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: Focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J. Am. Heart Assoc. 7, e009992 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"32266_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40885-021-00166-2","volume":"27","author":"HC Kim","year":"2021","unstructured":"Kim, H. C. et al. Korea hypertension fact sheet 2020: Analysis of nationwide population-based data. Clin. Hypertens. 27, 8 (2021).","journal-title":"Clin. Hypertens."},{"key":"32266_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507\u2013520. https:\/\/doi.org\/10.1001\/jama.2013.284427 (2014).","journal-title":"JAMA"},{"key":"32266_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry, T. N., Carland, J. E., Stocker, S. L., Sevastos, J. & Roberts, D. M. Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin. J. Am. Soc. Nephrol. 13, 1085\u20131095 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"32266_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","volume":"79","author":"D Pugh","year":"2019","unstructured":"Pugh, D., Gallacher, P. J. & Dhaun, N. Management of hypertension in chronic kidney disease. Drugs 79, 365\u2013379 (2019).","journal-title":"Drugs"},{"key":"32266_CR13","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/ndt\/16.11.2158","volume":"16","author":"H Herlitz","year":"2001","unstructured":"Herlitz, H. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: The Nephros Study. Nephrol. Dial. Transplant. 16, 2158\u20132165 (2001).","journal-title":"Nephrol. Dial. Transplant."},{"key":"32266_CR14","doi-asserted-by":"publisher","first-page":"c139","DOI":"10.1159\/000086714","volume":"101","author":"MS MacGregor","year":"2005","unstructured":"MacGregor, M. S., Deighan, C. J., Rodger, R. S. & Boulton-Jones, J. M. A prospective open-label randomised trial of quinapril and\/or amlodipine in progressive non-diabetic renal failure. Nephron. Clin. Pract. 101, c139-149 (2005).","journal-title":"Nephron. Clin. Pract."},{"key":"32266_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2215\/CJN.01110905","volume":"1","author":"Y Kanno","year":"2006","unstructured":"Kanno, Y., Takenaka, T., Nakamura, T. & Suzuki, H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin. J. Am. Soc. Nephrol. 1, 730\u2013737 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"32266_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641\u20132650 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"32266_CR17","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai, E. et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54, 2978\u20132986 (2011).","journal-title":"Diabetologia"},{"key":"32266_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","volume":"61","author":"G Fernandez-Juarez","year":"2013","unstructured":"Fernandez-Juarez, G. et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. Am. J. Kidney Dis. 61, 211\u2013218 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"32266_CR19","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267\u20132276 (2014).","journal-title":"N. Engl. J. Med."},{"key":"32266_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2215\/CJN.07460713","volume":"9","author":"PN Van Buren","year":"2014","unstructured":"Van Buren, P. N., Adams-Huet, B., Nguyen, M., Molina, C. & Toto, R. D. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 9, 295\u2013301 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"32266_CR21","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1681\/ASN.2018040443","volume":"29","author":"V Saglimbene","year":"2018","unstructured":"Saglimbene, V. et al. The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): A randomized, controlled trial. J. Am. Soc. Nephrol. 29, 2890\u20132899 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"32266_CR22","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433\u20132446 (2008).","journal-title":"N. Engl. J. Med."},{"key":"32266_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1592\/phco.29.9.1061","volume":"29","author":"M Abe","year":"2009","unstructured":"Abe, M., Okada, K., Maruyama, T. & Matsumoto, K. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Pharmacotherapy 29, 1061\u20131072 (2009).","journal-title":"Pharmacotherapy"},{"key":"32266_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/hr.2014.164","volume":"38","author":"S Kim-Mitsuyama","year":"2015","unstructured":"Kim-Mitsuyama, S. et al. Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study. Hypertens. Res. 38, 199\u2013207 (2015).","journal-title":"Hypertens. Res."},{"key":"32266_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10157-014-1044-4","volume":"19","author":"K Soji","year":"2015","unstructured":"Soji, K. et al. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study. Clin. Exp. Nephrol. 19, 631\u2013638 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"32266_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.amjhyper.2007.05.012","volume":"20","author":"R Fogari","year":"2007","unstructured":"Fogari, R. et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am. J. Hypertens. 20, 1092\u20131096 (2007).","journal-title":"Am. J. Hypertens."},{"key":"32266_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/hr.2013.63","volume":"36","author":"H Rakugi","year":"2013","unstructured":"Rakugi, H. et al. Combination therapy for hypertension in patients with CKD: a subanalysis of the combination therapy of hypertension to prevent cardiovascular events trial. Hypertens. Res. 36, 947\u2013958 (2013).","journal-title":"Hypertens. Res."},{"key":"32266_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","volume":"375","author":"GL Bakris","year":"2010","unstructured":"Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173\u20131181 (2010).","journal-title":"Lancet"},{"key":"32266_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","volume":"35","author":"R Thomas","year":"2008","unstructured":"Thomas, R., Kanso, A. & Sedor, J. R. Chronic kidney disease and its complications. Prim. Care 35, 329\u2013344 (2008).","journal-title":"Prim. Care"},{"key":"32266_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3\u20135: A network meta-analysis of randomised clinical trials. Drugs 80, 797\u2013811 (2020).","journal-title":"Drugs"},{"key":"32266_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jch.13429","volume":"21","author":"O Magvanjav","year":"2019","unstructured":"Magvanjav, O. et al. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. J. Clin. Hypertens. (Greenwich) 21, 91\u2013101 (2019).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"32266_CR32","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417\u20132428 (2008).","journal-title":"N. Engl. J. Med."},{"key":"32266_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jash.2012.07.004","volume":"6","author":"R Agarwal","year":"2012","unstructured":"Agarwal, R. & Sinha, A. D. Thiazide diuretics in advanced chronic kidney disease. J. Am. Soc. Hypertens. 6, 299\u2013308 (2012).","journal-title":"J. Am. Soc. Hypertens."},{"key":"32266_CR34","doi-asserted-by":"publisher","first-page":"s31","DOI":"10.1590\/1806-9282.66.s1.31","volume":"66Suppl 1","author":"R Watanabe","year":"2020","unstructured":"Watanabe, R. Hyperkalemia in chronic kidney disease. Rev. Assoc. Med. Bras. (1992) 66Suppl 1, s31\u2013s36 (2020).","journal-title":"Rev. Assoc. Med. Bras. (1992)"},{"key":"32266_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","volume":"46","author":"K Takaichi","year":"2007","unstructured":"Takaichi, K., Takemoto, F., Ubara, Y. & Mori, Y. Analysis of factors causing hyperkalemia. Intern. Med. 46, 823\u2013829 (2007).","journal-title":"Intern. Med."},{"key":"32266_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2215\/CJN.06630613","volume":"9","author":"DC Cerqueira","year":"2014","unstructured":"Cerqueira, D. C. et al. A predictive model of progression of CKD to ESRD in a predialysis pediatric interdisciplinary program. Clin. J. Am. Soc. Nephrol. 9, 728\u2013735 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"32266_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu, C. Y., Iribarren, C., McCulloch, C. E., Darbinian, J. & Go, A. S. Risk factors for end-stage renal disease: 25-year follow-up. Arch. Intern Med. 169, 342\u2013350 (2009).","journal-title":"Arch. Intern Med."},{"key":"32266_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12882-018-0942-1","volume":"19","author":"AS Go","year":"2018","unstructured":"Go, A. S. et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrol. 19, 146 (2018).","journal-title":"BMC Nephrol."},{"key":"32266_CR39","first-page":"2002","volume":"2010","author":"MA Abbasi","year":"2010","unstructured":"Abbasi, M. A., Chertow, G. M. & Hall, Y. N. End-stage renal disease. BMJ Clin. Evid. 2010, 2002 (2010).","journal-title":"BMJ Clin. Evid."},{"key":"32266_CR40","first-page":"109","volume":"3","author":"SB Ghaderian","year":"2014","unstructured":"Ghaderian, S. B. & Beladi-Mousavi, S. S. The role of diabetes mellitus and hypertension in chronic kidney disease. J. Renal. Inj. Prev. 3, 109\u2013110 (2014).","journal-title":"J. Renal. Inj. Prev."},{"key":"32266_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jch.13686","volume":"22","author":"S Park","year":"2020","unstructured":"Park, S. & Shin, J. Asian management of hypertension: Current status, home blood pressure, and specific concerns in Korea. J. Clin. Hypertens. (Greenwich) 22, 493\u2013496 (2020).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"32266_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.xkme.2020.04.002","volume":"2","author":"M Burnier","year":"2020","unstructured":"Burnier, M. Renin-angiotensin system blockade in advanced kidney disease: Stop or continue?. Kidney Med. 2, 231\u2013234 (2020).","journal-title":"Kidney Med."},{"key":"32266_CR43","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern Med. 162, 777\u2013784 (2015).","journal-title":"Ann. Intern Med."},{"key":"32266_CR44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"32266_CR45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh, M. L. Interrater reliability: the kappa statistic. Biochem. Med. (Zagreb) 22, 276\u2013282 (2012).","journal-title":"Biochem. Med. (Zagreb)"},{"key":"32266_CR46","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins, J. P. T. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"key":"32266_CR47","unstructured":"Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current\/chapter-14#Figure15_1_b (2023)."},{"key":"32266_CR48","unstructured":"Doing Meta-Analysis in R: A Hands on-Guide. Network Meta-Analysis. https:\/\/bookdown.org\/MathiasHarrer\/Doing_Meta_Analysis_in_R\/netwma.html (2022)."},{"key":"32266_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins, J. P. et al. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res. Synth. Methods 3, 98\u2013110 (2012).","journal-title":"Res. Synth. Methods"},{"key":"32266_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker, G. & Schwarzer, G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med. Res. Methodol. 15, 58 (2015).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32266-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32266-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32266-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T16:05:23Z","timestamp":1680883523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32266-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32266"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32266-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5727"}}